Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Common Equity (2016 - 2025)

Northwest Biotherapeutics' Common Equity history spans 16 years, with the latest figure at -$60.3 million for Q4 2025.

  • Quarterly results put Common Equity at -$60.3 million for Q4 2025, up 36.2% from a year ago — trailing twelve months through Dec 2025 was -$60.3 million (up 36.2% YoY), and the annual figure for FY2025 was -$60.3 million, up 36.2%.
  • Common Equity for Q4 2025 was -$60.3 million at Northwest Biotherapeutics, up from -$108.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$56.0 million in Q1 2023 to a low of -$353.2 million in Q1 2021.
  • The 5-year median for Common Equity is -$97.0 million (2024), against an average of -$126.2 million.
  • The sharpest move saw Common Equity tumbled 865.55% in 2021, then soared 73.8% in 2022.
  • Year by year, Common Equity stood at -$124.0 million in 2021, then fell by 3.32% to -$128.1 million in 2022, then skyrocketed by 48.66% to -$65.8 million in 2023, then crashed by 43.66% to -$94.5 million in 2024, then skyrocketed by 36.2% to -$60.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$60.3 million, -$108.6 million, and -$100.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.